Angiotensin II contractile effects in mouse colon: role for pre- and post-junctional AT1A receptors

Aim: This study investigates whether a local renin–angiotensin system (RAS) exists in mouse colon and whether angiotensin II (Ang II) may play a role in the regulation of the contractile activity. Methods: Isometric recordings were performed in vitro on the longitudinal muscle of mouse proximal and distal colon. Transcripts encoding for RAS components were investigated by RT-PCR. Results: Ang II caused, in both preparations, a concentration-dependent contractile effect, antagonized by losartan, AT1 receptor antagonist, but not by PD123319, AT2 receptor antagonist. The combination of losartan plus PD123319 caused no change on the Ang II-induced contraction than losartan alone. Tetrodotoxin, neural blocker, reduced the contractile response to Ang II in the proximal colon, whilst the response was abolished in the distal colon. In both preparations, atropine, muscarinic receptor antagonist, or SR140333, NK1 receptor antagonist, reduced the Ang II responses. Ondansetron, 5-HT3 receptor antagonist, SR48968, NK2 receptor antagonist, or hexamethonium, nicotinic receptor antagonist, were ineffective. The joint application of atropine and SR140333 produced no additive effect. Atropine reduced NK1-induced contraction. Transcripts encoding RAS components were detected in the colon samples. However, just AT1A mRNA was expressed in both preparations, and AT2 mRNA was expressed only in the distal colon. Conclusion: In the murine colon, local RAS may play a significant role in the control of contractile activity. Ang II positively modulates the spontaneous contractile activity via activation of post-junctional and pre-junctional AT1A receptors, the latter located on the enteric neurones, modulating the release of tachykinins and acetylcholine

Angiotensin II positively modulates the spontaneous contractile activity of mouse and human colon via activation of AT1 receptors.

Objective: Angiotensin II (Ang II) is a potent smooth muscle contractile neurohumoral agonist but has not been much investigated with regard to gastrointestinal motor activity. Ang II effects are mediated by specific receptors, the Ang II type 1 (AT1) and the Ang II type 2 (AT2) receptors, which are well expressed in the gut. In this study we evaluated the effects of Ang II on the contractile activity of longitudinal muscle from mouse and human colon and we analysed the subtype(s) of receptors involved in the observed effects. Methods: Mechanical responses to Ang II, in the absence or in the presence of different drugs, were assessed in vitro in colonic longitudinal muscle from mice and humans, as changes in isometric tension. Results: In the murine proximal and distal colon Ang II induced a concentration-dependent muscular contraction, which was reduced by the AT1 receptor antagonist, losartan, but it was not affected by the AT2 receptor antagonist, PD123319. Pretreatment with TTX, sodium voltage-gated neural channel blocker, partially reduced the contractile response to Ang II in the proximal colon, while abolished it in the distal colon. Atropine, muscarinic receptor antagonist, or SR140333, NK1 receptor antagonist, reduced the TTX-sensitive excitatory effects induced by Ang II in both preparations. On the contrary, hexamethonium, nicotinic receptor antagonists, ondansetron, 5-HT3 receptor antagonist, or SR48968, NK2 receptor antagonist, were ineffective. The contraction induced by a selective NK1 receptor agonist was reduced by atropine, whilst SR140333 did not affected carbachol inducing muscular contraction. Ang II induced a muscular contraction even in the human distal colonic longitudinal muscle preparations. The concentration–response curve was shifted to the right by losartan but it was unaffected by PD123319. TTX and atropine partially antagonized the response to Ang II. Conclusion: In the longitudinal muscle preparations from mouse and human colon Ang II positively modulates the spontaneous contractile activity via activation of post-junctional and pre-junctional AT1 receptors, the latter located on the enteric nerves and modulating the release of tachykinins and acethylcoline. In mouse tachykinergic neurons and cholinergic neurons are sequentially recruited by Ang II to induce muscular contraction

Aging modifies receptor expression but not muscular contractile response to angiotensin II in rat jejunum

: The involvement of renin-angiotensin system in the modulation of gut motility and age-related changes in mRNA expression of angiotensin (Ang II) receptors (ATR) are well accepted. We aimed to characterize, in vitro, the contractile responses induced by Ang II, in jejunum from young (3-6 weeks old) and old rats (≥ 1 year old), to evaluate possible functional differences associated to changes in receptor expression. Mechanical responses to Ang II were examined in vitro as changes in isometric tension. ATR expression was assessed by qRT-PCR. Ang II induced a contractile effect, antagonized by losartan, AT1R antagonist, and increased by PD123319, AT2R antagonist, as well by neural blocker ω-conotoxin and by nitric oxide (NO) synthase inhibitor. No difference in the response was observed between young and old groups. AT1 receptor-mediated contractile response was decreased by U-73122, phospholipase C (PLC) inhibitor; or 2-aminoethoxy-diphenylborate (2-APB), inositol triphosphate (IP3) receptor inhibitor; or nifedipine, L-type calcium channel blocker. Age-related changes in the expression of both AT1 receptor subtypes, AT1a and AT1b, and of AT2 receptors were detected. In conclusion, Ang II modulates the spontaneous contractility of rat jejunum via postjunctional AT1 receptors, involving Ca2+ mobilization from intracellular stores, via PLC/IP3 pathway, and Ca2+ influx from extracellular space, via L-type channels. Prejunctional AT2 receptors would counteract AT1 receptor effects, via NO synthesis. The observed age-related differences in the expression of all AT receptor subtypes are not reflected in the muscular contractile response to Ang II

Chemical Characterization and Cytotoxic and Antioxidant Activity Evaluation of the Ethanol Extract from the Bulbs of Pancratium maritimun Collected in Sicily

P. maritimum L., belonging to the Amaryllidaceae family, is a species that grows on beaches and coastal sand dunes mainly on both sides of the Mediterranean Sea and Black Sea, the Middle East, and up to the Caucasus region. It has been largely investigated due to its several interesting biological properties. With the aim of providing new insights into the phytochemistry and pharmacology of this species, the ethanolic extract of the bulbs from a local accession, not previously studied, growing in Sicily (Italy), was investigated. This chemical analysis, performed by mono- and bi-dimensional NMR spectroscopy, as well as LC-DAD-MSn, allowed to identify several alkaloids, three of which were never detected in the genus Pancratium. Furthermore, the cytotoxicity of the preparation was assessed in differentiated human Caco-2 intestinal cells by trypan blue exclusion assay, and its antioxidant potential was evaluated using the DCFH-DA radical scavenging method. The results obtained demonstrate that P. maritimum bulbs’ extract exerts no cytotoxic effect and is able to remove free radicals at all the concentrations tested

In vivo Micro-computed tomography imaging of adipose tissue of mice fed Sicilian pistachio

In obesity condition the adipose tissue undergoes molecular and cellular alterations affecting systemic metabolism via the release of different pro-inflammatory mediators. Nut-derived polyphenols and fatty acids have a documented role in the modulation of energy metabolism and antiobesity effect. We investigate the effects of Pistachia vera nuts on body fat mass and its distribution in a mouse models of obesity by Micro-computed tomography (CT). For this purpose, three groups of C57BL/6J male mice were fed for 16 weeks with a standard chow, a high fat diet (HFD) or HFD supplemented with pistachio harvested in plantation of the valley of the Platani river (Sicily). Fatty acids extraction from Pistachia vera nuts was carried out and analysed by a gas-chromatographic technique for contributing 20% of total diet energy. Total body fat mass was estimated and compared between groups by micro-CT (Quantum FX Micro CT scanner). Furthermore, the effects of pistachio consumption on total cholesterol, triglycerides, fat liver accumulation, adipose tissue inflammatory cytokines (TNFα and IL-1β) expression and serum ROS levels were also evaluated. The micro-CT slices and three-dimensional image stacks of control and obese mice showed a reduced body fat deposit and less visceral fat in mice fed HFD supplemented with pistachios. Furthermore, cholesterol and triglycerides levels, hepatic lipid accumulation, pro-inflammatory cytokines and serum ROS levels were significantly reduced in mice fed HFD supplemented with pistachio compared with the HFD mice. Our results suggest that pistachio consumption could have counteracting effects on metabolic dysfunctions in obesity through acting on the fat mass. In particular, it lower the accumulation of visceral and subcutaneous fat that could be responsible of lower level of circulating and hepatic lipids and of the decreased inflammatory condition

Investigating the inhibition of FTSJ1 a tryptophan tRNA-specific 2’-O-methyltransferase by NV TRIDs, as a mechanism of readthrough in nonsense mutated CFTR

Abstract: Cystic Fibrosis (CF) is an autosomal recessive genetic disease caused by mutations in the CFTR gene, coding for the CFTR chloride channel. About 10% of the CFTR gene mutations are "stop" mutations, which generate a Premature Termination Codon (PTC), thus synthesizing a truncated CFTR protein. A way to bypass PTC relies on ribosome readthrough, which is the ri-bosome’s capacity to skip a PTC, thus generating a full-length protein. “TRIDs” are molecules exerting ribosome readthrough; for some, the mechanism of action is still under debate. We in-vestigate a possible mechanism of action (MOA) by which our recently synthesized TRIDs, namely NV848, NV914, and NV930, could exert their readthrough activity by in silico analysis and in vitro studies. Our results suggest a likely inhibition of FTSJ1, a tryptophan tRNA-specific 2’-O-methyltransferase

Anionic Methacrylate Copolymer Microparticles for the Delivery of Myo-Inositol Produced by Spray-Drying: In Vitro and In Vivo Bioavailability

: In this study, a new micro delivery system based on an anionic methacrylate copolymer, able to improve the biological response of myo-inositol by daily oral administration, was manufactured by spray-drying. It has an ideal dose form for oral administration, with an experimental drug loading (DL)% of 14% and a regulated particle size of less than 15 μm. The new formulation features an improvement on traditional formulations used as a chronic therapy for the treatment of polycystic ovary syndrome. The microparticles' release profile was studied and ex vivo porcine intestinal mucosa permeation experiments were performed to predict potential improvements in oral absorption. Batch n. 3, with the higher Eudragit/MI weight ratio (ratio = 6), showed the best-modified release profiles of the active ingredient, ensuring the lowest myo-inositol loss in an acidic environment. The in vivo evaluation of the myo-inositol micro delivery system was carried out in a rat animal model to demonstrate that the bioavailability of myo-inositol was increased when compared to the administration of the same dosage of the pure active ingredient. The AUC and Cmax of the loaded active molecule in the micro delivery system was improved by a minimum of 1.5 times when compared with the pure substance, administered with same dosage and route. Finally, the increase of myo-inositol levels in the ovary follicles was assessed to confirm that a daily administration of the new formulation improves myo-inositol concentration at the site of action, resulting in an improvement of about 1.25 times for the single administration and 1.66 times after 7 days of repeated administration when compared to pure MI

Readthrough Approach Using NV Translational Readthrough-Inducing Drugs (TRIDs): A Study of the Possible Off-Target Effects on Natural Termination Codons (NTCs) on TP53 and Housekeeping Gene Expression

Nonsense mutations cause several genetic diseases such as cystic fibrosis, Duchenne muscular dystrophy, β-thalassemia, and Shwachman–Diamond syndrome. These mutations induce the formation of a premature termination codon (PTC) inside the mRNA sequence, resulting in the synthesis of truncated polypeptides. Nonsense suppression therapy mediated by translational readthrough-inducing drugs (TRIDs) is a promising approach to correct these genetic defects. TRIDs generate a ribosome miscoding of the PTC named “translational readthrough” and restore the synthesis of full-length and potentially functional proteins. The new oxadiazole-core TRIDs NV848, NV914, and NV930 (NV) showed translational readthrough activity in nonsense-related in vitro systems. In this work, the possible off-target effect of NV molecules on natural termination codons (NTCs) was investigated. Two different in vitro approaches were used to assess if the NV molecule treatment induces NTC readthrough: (1) a study of the translational-induced p53 molecular weight and functionality; (2) the evaluation of two housekeeping proteins’ (Cys-C and β2M) molecular weights. Our results showed that the treatment with NV848, NV914, or NV930 did not induce any translation alterations in both experimental systems. The data suggested that NV molecules have a specific action for the PTCs and an undetectable effect on the NTCs

Industrial-produced lemon nanovesicles ameliorate experimental colitis-associated damages in rats via the activation of anti-inflammatory and antioxidant responses and microbiota modification

Plant-derived nanovesicles (PDNVs) have recently emerged as natural delivery systems of biofunctional compounds toward mammalian cells. Considering their already described composition, anti-inflammatory properties, stability, and low toxicity, PDNVs offer a promising path for developing new preventive strategies for several inflammatory diseases, among which the inflammatory bowel disease (IBD). In this study, we explore the protective effects of industrially produced lemon vesicles (iLNVs) in a rat model of IBD. Characterization of iLNVs reveals the presence of small particles less than 200 nm in size and a profile of bioactive compounds enriched in flavonoids and organic acids with known beneficial properties. In vitro studies on human macrophages confirm the safety and anti-inflammatory effects of iLNVs, as evidenced by the reduced expression of pro-inflammatory cytokines and increased levels of anti-inflammatory markers. As evidenced by in vivo experiments, pre-treatment with iLNVs significantly alleviates symptoms and histological features in 2,4 dinitrobenzensulfuric acid (DNBS)-induced colitis in rats. Molecular pathway analysis reveals modulation of NF-κB and Nrf2, indicating anti-inflammatory and antioxidant effects. Finally, iLNVs affects gut microbiota composition, improving the consistent colitis-related alterations. Overall, we demonstrated the protective role of industrially produced lemon nanovesicles against colitis and emphasized their potential in managing IBD through multifaceted mechanisms